Alexander Horspool
Associate Director, Innovation, Biotherapeutics Discovery
Boehringer Ingelheim
Wolfgang Colsman
Founder & CEO
ZONTAL
With nearly 30 years of visionary leadership, Wolfgang Colsman serves as the Chief Executive Officer of ZONTAL, a pioneering enterprise platform transforming the way organizations manage and preserve their digital information. Under his leadership, ZONTAL has become a catalyst for change across industries, redefining how data is captured, connected, and safeguarded for long-term value.
Before founding ZONTAL, Wolfgang spent over two decades at OSTHUS as Chief Innovation Officer and Chief Technology Officer, where he guided large-scale digital transformation initiatives. His ability to bridge cutting-edge technology with real-world business needs helped establish OSTHUS as a trusted, vendor-agnostic partner driving innovation for global enterprises.
Beyond his corporate achievements, Wolfgang has left a lasting mark on the life sciences and technology ecosystems through his leadership at the Allotrope Foundation and the Pistoia Alliance Methods Hub project. By championing data standards, interoperability, and collaborative infrastructures, he has empowered industries to break down silos, accelerate discovery, and unlock new opportunities for digital transformation. These efforts continue to shape how organizations think about data as a strategic asset rather than a byproduct.
Recognized for his ability to anticipate technological shifts and inspire collaborative progress, Wolfgang has become a respected voice in the digital landscape—bringing together vision, strategy, and execution to create sustainable impact.
ZONTAL
Website: zontal.io
ZONTAL provides the premier data platform tailored for the life science industry. Our platform is at the forefront of digital transformation, delivering innovative solutions that address the intricate challenges faced by large-scale enterprises. Our services streamline IT processes, facilitate the integration of AI/ML applications, accelerate product time-to-market, and enhance regulatory compliance.
With a global presence encompassing the US, Europe, and Asia, ZONTAL is well positioned to offer seamless support to our clients worldwide. Our network of dedicated integration and service partners enables us to deliver our expertise and solutions in any country and across all time zones, ensuring our customers receive unparalleled support wherever they are.
The idea of a “one-click” Biologics License Application (BLA) has become the ultimate benchmark for what AI could enable in drug development — a world where data moves seamlessly from discovery to submission, with every result, dataset, and citation verified, traceable, and regulator-ready. But how far are we actually from that reality?
This session explores the technologies, infrastructures, and cultural shifts needed to bring automation to one of the most complex and high-stakes processes in life sciences: regulatory submission. The discussion will cut through the hype to define what “submission-grade AI” really means, the challenges that still stand in the way of full automation, and what it will take to build the regulatory trust required to get there.
Join us as we examine the future of AI-driven submissions — and ask the provocative question: could the next BLA really be submitted with a single click?
Farouk Daher
Head of Operations
Bluenote
Subha Madhavan
Vice President & Head of Clinical AI / ML
Pfizer
Dr. Eliezer Katz
CMO
Eledon Pharmaceuticals
Dr. Katz is an experienced transplant surgeon and a leader in clinical development in the pharmaceutical industry. Currently, Dr. Katz is the chief medical officer of Eledon Pharmaceutical. Before joining Eledon, Dr. Katz was CMO of eGenesis, a company in the xenotransplantation field. Previously, Dr. Katz served as Vice President and clinical development lead at Viela Bio and Horizon Therapeutics, where he was responsible for developing novel medications for autoimmune-related diseases and organ transplantation.
Dr. Katz earned his MD degree from the Hebrew University-Hadassah Medical School in Jerusalem, Israel.
Dr. Katz joined Viela Bio/Horizon following 30 years of combined academic and pharmaceutical career in the areas of organ transplantation, immunology, and immune-induced diseases.
His academic career as a transplant surgeon spanned 20 years, including directorship of two transplantation programs. The director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. During his tenure as a transplant surgeon, Dr. Katz implemented techniques for split liver and living donor liver transplantation, was actively involved in policy making related to organ donation and allocation and led efforts to increase organ donation.
After joining the pharmaceutical industry, Dr. Katz served as the vice president at CTI clinical trial and consulting services, as senior director in transplantation at Medicine Development Group, Pfizer Inc., and at Medimmune/AstraZeneca as a senior director at RIA (respiratory, inflammation, and autoimmunity), where he oversaw clinical development in neuro-inflammation, inflammatory bowel disease, and myositis.
Dr. Katz is an author of more than 60 peer-reviewed publications.
Reed Few
Director of Data Science & External Innovation
J&J
Reed Few is Director of External Innovation for Data Science and Digital Health at Johnson and Johnson Innovative Medicine, R&D. With a background spanning real-world data, predictive modeling, and precision medicine, Reed is passionate about finding ways to combine data and AI to bring therapies from concept to approval, faster. In her current role, she looks for partnerships that will help to design better, more diverse clinical trials, improve operational efficiencies, and find digital endpoints that better reflect how patients live and feel in the real world. As of late, her focus has been on initiatives applying generative AI and large language models to accelerate document creation across preclinical, CMC, and clinical domains – advancing smarter, faster, and more connected drug development.
Bluenote
Website: www.bluenotehealth.com
Bluenote helps scientists, researchers, and medical writers accelerate critical workflows by 50–75%—so you can spend less time on paperwork and more time advancing life-saving therapies.
Learn how scalable, cloud-based AI infrastructure accelerates model training, data integration, and collaborative research across global drug discovery teams.
Kevin Cochrane
Chief Marketing Officer
Vultr
Kevin is a 25+ year pioneer of the digital experience space. Now at Vultr, Kevin is now working to build Vultr's global brand presence as a leader in the independent Cloud platform market.
Vultr
Website: www.vultr.com
Vultr, founded in 2014, is on a mission to empower developers and businesses by simplifying the deployment of infrastructure via its advanced cloud platform. Vultr is strategically located in 32 data centers around the globe and provides frictionless provisioning of Cloud Compute, Cloud GPU, Cloud Storage, Networking, and Bare Metal.
- Explore practical strategies for building high-quality, diverse datasets that reduce bias and improve model performance across drug discovery pipelines.
Nevin Gerek Ince
Director, Data & Solutions Engineering
Novo Nordisk
Nikhil Tyagi
Senior Manager, Wireless Device Innovation Strategy
Verizon
Nikhil Tyagi is a recognized leader in next-generation technology, with a proven track record at the intersection of AI infrastructure, wireless innovation, and immersive computing. As Senior Manager of Wireless Device Innovation at Verizon, he leads strategic initiatives for breakthrough device categories that integrate AI, XR (AR/VR), and advanced connectivity.
Previously, Nikhil held key roles at Humane, Meta, and Apple, where he helped shape pioneering AI and XR experiences—from developing on-device intelligence for ambient computing, to architecting scalable XR systems and wearable platforms. His cross-functional expertise spans edge AI, spatial computing, and system-level wireless design, making him a pivotal voice in the evolving landscape of AI-driven interfaces."
Lisa Spelman
CEO
Cornelis Networks
Lisa Spelman is CEO of Cornelis Networks. As CEO, Lisa is responsible for the overall management of the company. She brings to the company more than two decades of executive leadership experience, most recently serving as corporate vice president in the Data Center & AI Group and general manager of Xeon Products and Solutions at Intel Corporation. During her tenure, she expanded Xeon’s capabilities to accelerate AI workloads, establishing CPUs as a leading inference engine across the industry. Lisa also held several senior leadership roles within Intel’s IT organization, including infrastructure operations and engineering, as well as positions in finance, data center product and brand marketing, and sales. She is a graduate of the University of Washington, with a degree in business administration.
Yuriy Bulygin
Co-Founder & CEO
Eclypsium
Yuriy Bulygin is Co-Founder & CEO at Eclypsium. Prior to founding Eclypsium, Yuriy led the Advanced Threat Research team at Intel Security and the microprocessor security analysis team at Intel Corporation. He also created CHIPSEC, the open-source firmware and hardware security assessment framework.